



Financial Tear Sheet

Corporate Profile

Cambrex Corporation is a custom development and manufacturing organization that specializes in products and services that accelerate the development and commercialization of small molecule therapeutics.

We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.

Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage forms.

Primary IR Contact

Stephanie LaFiura
Investor Relations Associate
Phone: 201-804-3037
Fax: 201-804-9852
E-mail:
stephanie.lafiura@cambrex.com

Stock Performance

Symbol CBM (Common Stock)

Exchange NYSE (US Dollar)

Price \$56.05

Change (%) ▲ 0.35 (0.63%)

Volume 206,620

Data as of July 20, 2018 4:02 p.m. ET

Management

Steven M. Klosk President and Chief Executive Officer

Shawn P. Cavanagh Executive Vice President and Chief Operating Officer

Samantha M. Hanley Vice President, General Counsel and Secretary

Gregory P. Sargen Executive Vice President, Corporate Development and Strategy

Tom Vadaketh Executive Vice President and Chief Financial Officer

Recent Headlines & Events

There are currently no events scheduled.

Date	Title
June 12, 2018	Cambrex Expands Generic API Research and Development Capabilities at Milan, Italy Site
June 01, 2018	Cambrex to Present at the Jefferies 2018 Global Healthcare Conference
May 31, 2018	Cambrex Invests \$5 Million in New Laboratory Expansion at its Karlskoga, Sweden Facility

SEC Filings

Filing Date	Form
July 03, 2018	4
June 12, 2018	4
May 09, 2018	4
May 09, 2018	4

Data provided by Nasdaq. Minimum 15 minutes delayed.